Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia

A. Argiris, G. S.A. Longo, R. Gorlick, W. Tong, P. Steinherz, J. R. Bertino

Research output: Contribution to journalArticle

12 Scopus citations


Acute myelocytic leukemia (AML) is a malignancy that is intrinsically resistant to methotrexate (MTX). AML blasts, when incubated with radiolabeled MTX, form lower amounts of long chain polyglutamates compared to acute lymphocytic leukemia (ALL) blasts, thus providing an explanation for their lack of responsiveness to MTX. Leukemic blasts obtained from two children with acute megakaryocytic leukemia (M7 subtype) when incubated with radiolabeled MTX showed increased accumulation of total as well as long chain MTX polyglutamates, comparable to levels previously demonstrated in another subtype of AML, acute monocytic leukemia (M5), as well as in blasts from patients with pre-B ALL. We suggest that M7-AML patients with blasts showing increased MIX polyglutamylation might benefit from treatment with MTX.

Original languageEnglish (US)
Pages (from-to)886-889
Number of pages4
Issue number6
StatePublished - Jan 1 1997



  • Acute megakaryocytic leukemia
  • Acute myelocytic leukemia
  • Methotrexate
  • Polyglutamylation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this